Ad
related to: cost of pravastatin 40 mgWorking to be "the most powerful patient advocate in America" - Forbes
Search results
Results from the WOW.Com Content Network
Pravastatin has undergone over 112,000 patient-years of double-blind, randomized trials using the 40 mg, once-daily dose and placebos.These trials indicate pravastatin is well tolerated and displays few noncardiovascular abnormalities in patients.
Within the year of 2014, the cost of prescriptions had increased by at least 11.4% and 58% within the last eight years. The average cost for a month supply of brand-name drugs can run up to a couple of hundred US dollars, whereas in Canada and Great Britain the same medication could cost up to $40 US dollars.
Pravastatin belongs to the group called statins. [2] It reduces total blood cholesterol by blocking the action of 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA) reductase, an enzyme in the liver involved in the production of cholesterol. [ 2 ]
Lipids are measured in milligrams per deciliter or mg/dL. The right lipid levels for you will depend on your age, gender, and other factors. ... Pravastatin. Simvastatin. Atorvastatin.
For example, some American consumers still pay an average of $50 a month for the generic drug pravastatin to lower cholesterol. But you The Best Deal Around: $4 Generics
Teva Pharmaceuticals agreed to pay more than $200 million in fines and divest a key generic drug treating cholesterol to settle price-fixing charges from the US Department of Justice, the agency ...
The Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 trial, also known as PROVE-IT TIMI 22, was a randomized, double-blind, clinical trial that recruited 4,162 people admitted within 10 days of an acute coronary event and randomised them to the lipid-lowering drugs pravastatin (40 mg) or atorvastatin (80 mg) and a 10-day course of the ...
The enrollment period was from February 1989 through September 1991. Participants were randomly assigned to receive either pravastatin (40 mg daily) or a placebo. The primary endpoint was the incidence of nonfatal myocardial infarction and death from CHD.